REMICADE® (infliximab)
AXERT® (almotriptan malate) Tablets
CONCERTA® (methylphenidate HCI) Extended-release Tablets CII
DARZALEX™ (daratumumab)
DOXIL® (doxorubicin HCl liposome injection)
DURAGESIC® (fentanyl transdermal system) CII
EDURANT® (rilpivirine)
ELMIRON® (pentosan polysulfate sodium) Capsules
HALDOL® (haloperidol)
HALDOL® DECANOATE (haloperidol)
HALDOL® DECANOATE
INTELENCE® (etravirine)
INVEGA® (paliperidone)
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA SUSTENNA®
INVEGA TRINZA® (paliperidone palmitate) extended-release injectable suspension 273 mg, 410 mg, 546 mg, or 819 mg
INVEGA TRINZA®
INVOKAMET® (canagliflozin/metformin HCl) tablets
INVOKAMET® XR (canagliflozin/metformin HCl extended-release) tablets
INVOKAMET® XR
INVOKANA® (canagliflozin)
LEVAQUIN® (levofloxacin) Tablets
OLYSIO® (simeprevir)
OneTouch® Meters and Test Strips
ORTHO TRI-CYCLEN® Lo (norgestimate/ethinyl estradiol)
ORTHO TRI-CYCLEN® Lo
PANCREAZE® (pancrelipase) Delayed-Release Capsules
PREZCOBIX® (darunavir 800 mg/ cobicistat 150 mg) tablets
PREZISTA® (darunavir) tablets
PROCRIT® (epoetin alfa)
RAZADYNE® ER (galantamine HBr) Extended-Release Capsules
RAZADYNE® ER
REMICADE® (infliximab)
RISPERDAL® (risperidone)
RISPERDAL CONSTA® (risperidone)
RISPERDAL CONSTA®
SIMPONI® (golimumab)
SIMPONI ARIA® (golimumab)
SIMPONI ARIA®
SPORANOX® (itraconazole)
STELARA® (ustekinumab)
SYLVANT® (siltuximab)
TOPAMAX® (topiramate) Tablets
XARELTO® (rivaroxaban)
YONDELIS® (trabectedin)
ZYTIGA® (abiraterone acetate)

Need help paying for your REMICADE® (infliximab) medication?

We want to guide you to programs that may help. Here you'll find the medication assistance programs available for REMICADE®. We have also listed most of the eligibility requirements. Call the programs or visit their websites to learn more.

Janssen CarePath

877-CarePath

(877-227-3728)

Monday-Friday, 8 AM to 8 PM ET

To view programs that are best suited for you, select your insurance status for REMICADE® or view all assistance programs

You may be eligible for one or more of the following programs:

To view programs that are best suited for you, select your insurance status for REMICADE® or view all assistance programs

You may be eligible for one or more of the following programs:

At the current time, patient affordability programs for the selected insurance option are not available for this product. Please check back, as programs change.

The following programs are affiliated with Janssen.

They are updated on a regular basis. Be sure to visit the program site for additional information.

Janssen CarePath Savings Program for REMICADE®

If you are eligible, you may be able to lower your out-of-pocket costs for REMICADE®, including deductible, co-pay, and coinsurance medication costs. With Janssen CarePath Savings Program for REMICADE®, eligible patients pay just $5 for each infusion for your REMICADE® medication costs, with a $20,000 maximum program benefit each calendar year. Patients using Medicare, Medicaid or any other federally funded programs to pay for REMICADE® are not eligible to participate in the program. Before the calendar year ends, you will receive information and eligibility requirements for continued participation in the program. There is no income requirement.

Click here for full eligibility requirements

The following programs are not affiliated with Janssen.

Be sure to contact the programs directly to get details on eligibility and application requirements, and to see if they have funding available to help you.

Johnson & Johnson Patient Assistance Foundation

Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) provides free prescription medications to eligible individuals who do not have insurance coverage for their medicines and do not have adequate financial resources to pay for them. Please contact a JJPAF program specialist at 800-652-6227 (9 AM to 6 PM ET) or visit the foundation website at JJPAF.org to see if you might qualify for assistance.

State-Sponsored Programs

Some states sponsor prescription financial assistance programs, each with its own eligibility requirements.

Find out if your state has a program that can help you »

Medicare Savings Program

Many states have programs for people with limited income and resources that pay some or all of Medicare's premiums and may pay Medicare deductibles and coinsurance. Find out if your state has a program that can help you.

Medicare Part D Extra Help — Low-Income Subsidy

Medicare patients who have limited income and resources may qualify for "extra help" to pay for prescription drugs. The Low-Income Subsidy (LIS) program from Medicare provides financial assistance for patients who may otherwise be unable to afford the costs associated with their Medicare Part D plan.

Those who are eligible for LIS may:

  • Receive assistance paying their monthly premium
  • Have a reduced or no deductible
  • Have reduced or no prescription coinsurance and co-payments
  • Have no gap in coverage

Good Days from CDF®

This foundation provides financial assistance to those eligible for co-pays and travel costs associated with treatment.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Crohn's Disease, Plaque Psoriasis

Patient Access Network Foundation

This foundation provides financial assistance to those eligible for their out-of-pocket medication expenses.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Ankylosing Spondylitis, Crohn's Disease, Plaque Psoriasis, Rheumatoid Arthritis

Patient Advocate Foundation

This foundation provides financial assistance to those eligible for their out-of-pocket medication expenses.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Ankylosing Spondylitis, Crohn's Disease, Plaque Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis

The Assistance Fund

This program offers financial assistance for co-pays, premiums, and basic healthcare needs for those eligible.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis

The HealthWell Foundation®

This foundation provides financial assistance to those eligible for co-insurance, co-payments, healthcare premiums and deductibles for certain medications.

This foundation may be able to help you if:

  • You have private/commercial or government insurance coverage for REMICADE®
    AND
  • You are taking REMICADE® to treat Crohn's Disease, Ulcerative Colitis
June 22, 2016
Expand
Expand

IMPORTANT SAFETY INFORMATION

INDICATIONS

REMICADE® is a prescription medication used to treat:

Crohn's Disease

  • Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn's disease who haven't responded well to other therapies

Pediatric Crohn's Disease

  • Can reduce signs and symptoms and induce and maintain remission in children (ages 6-17) with moderately to severely active Crohn's disease who haven't responded well to other therapies

Ulcerative Colitis

  • Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active ulcerative colitis who haven't responded well to other therapies

Pediatric Ulcerative Colitis

  • Can reduce signs and symptoms and induce and maintain remission in children (ages 6-17) with moderately to severely active ulcerative colitis who haven't responded well to other therapies

Rheumatoid Arthritis

  • Can reduce signs and symptoms, help stop further joint damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis, in combination with methotrexate

Psoriatic Arthritis

  • Can reduce signs and symptoms of active arthritis, help stop further joint damage, and improve physical function in patients with psoriatic arthritis

Ankylosing Spondylitis

  • Can reduce signs and symptoms in patients with active ankylosing spondylitis

Plaque Psoriasis

  • Approved for the treatment of adult patients with chronic severe (extensive and/or disabling) plaque psoriasis under the care of a physician who will determine if REMICADE® is appropriate considering other available therapies

Only your doctor can recommend a course of treatment after checking your health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.

Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. Hepatosplenic T-cell lymphoma, a rare form of fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine. For children and adults taking TNF blockers, including REMICADE®, the chances of getting lymphoma or other cancers may increase.

You should discuss any concerns about your health and medical care with your doctor.

What should I tell my doctor before I take REMICADE®?

You should let your doctor know if you have or ever had any of the following:

Also tell your doctor if you:

What should I watch for and talk to my doctor about before or while taking REMICADE®?

The following serious (sometimes fatal) side effects have been reported in people taking REMICADE®.

You should tell your doctor right away if you have any of the signs listed below:

The more common side effects with REMICADE® are respiratory infections (that may include sinus infections and sore throat), headache, rash, coughing and stomach pain.

Please read the Medication Guide for REMICADE® and discuss it with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

039671-150902

IMPORTANT SAFETY INFORMATION

INDICATIONS

REMICADE® is a prescription medication used to treat:

Crohn's Disease

  • Can reduce signs and symptoms and induce and maintain remission in adult patients with moderately to severely active Crohn's disease who haven't responded well to other therapies

Pediatric Crohn's Disease

  • Can reduce signs and symptoms and induce and maintain remission in children (ages 6-17) with moderately to severely active Crohn's disease who haven't responded well to other therapies

Ulcerative Colitis

  • Can reduce signs and symptoms, induce and maintain remission, promote intestinal healing, and reduce or stop the need for steroids in adult patients with moderately to severely active ulcerative colitis who haven't responded well to other therapies

Pediatric Ulcerative Colitis

  • Can reduce signs and symptoms and induce and maintain remission in children (ages 6-17) with moderately to severely active ulcerative colitis who haven't responded well to other therapies

Rheumatoid Arthritis

  • Can reduce signs and symptoms, help stop further joint damage, and improve physical function in patients with moderately to severely active rheumatoid arthritis, in combination with methotrexate

Psoriatic Arthritis

  • Can reduce signs and symptoms of active arthritis, help stop further joint damage, and improve physical function in patients with psoriatic arthritis

Ankylosing Spondylitis

  • Can reduce signs and symptoms in patients with active ankylosing spondylitis

Plaque Psoriasis

  • Approved for the treatment of adult patients with chronic severe (extensive and/or disabling) plaque psoriasis under the care of a physician who will determine if REMICADE® is appropriate considering other available therapies

Only your doctor can recommend a course of treatment after checking your health condition. REMICADE® (infliximab) can cause serious side effects such as lowering your ability to fight infections. Some patients, especially those 65 years and older, have had serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE®.

Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. Hepatosplenic T-cell lymphoma, a rare form of fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE® and azathioprine or 6-mercaptopurine. For children and adults taking TNF blockers, including REMICADE®, the chances of getting lymphoma or other cancers may increase.

You should discuss any concerns about your health and medical care with your doctor.

What should I tell my doctor before I take REMICADE®?

You should let your doctor know if you have or ever had any of the following:

Also tell your doctor if you:

What should I watch for and talk to my doctor about before or while taking REMICADE®?

The following serious (sometimes fatal) side effects have been reported in people taking REMICADE®.

You should tell your doctor right away if you have any of the signs listed below:

The more common side effects with REMICADE® are respiratory infections (that may include sinus infections and sore throat), headache, rash, coughing and stomach pain.

Please read the Medication Guide for REMICADE® and discuss it with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

039671-150902